WebNov 11, 2024 · In addition, Rachel leads business development activities at Inception Therapeutics, a Versant backed incubator. She is a neurobiologist by training with more than 10 years of experience sourcing new opportunities and leading transactions in business development and portfolio strategy roles across nonprofit and the biotech industry. WebApr 13, 2024 · Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 16.67% and 20.91%, respectively, for the quarter ended February 2024. ... The franchise owned by Ambanis and Reliance Industries has won a record five titles since the league's inception. Zacks. Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue …
Ception Therapeutics - Crunchbase Company Profile & Funding
WebChinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases December 19, 2024 Pipeline Therapeutics Completes $30 Million Series B Financing August 22, 2024 Chinook therapeutics raises $65 million series a financing to advance precision medicines for kidney diseases May 16, 2024 WebHeadquartered in San Diego, Inception Therapeutics is focused on partnering with pioneering academics to launch bold new companies in breakthrough areas of biology. Synopsis Based in Switzerland, Ridgeline Therapeutics extends our model of company creation to Europe. Ridgeline has laboratories in Basel Technology Park. Synopsis crown earth
Rachel Lane, PhD — Coda Biotherapeutics
WebOct 30, 2024 · INCEPTION THERAPEUTICS, INC. branch Company Number 4208719 Previous Company Numbers C4208719 Status Active Incorporation Date 30 October 2024 (over 4 years ago) Company Type Stock Corporation - Out of State - Stock Jurisdiction California (US) Branch Branch of INCEPTION THERAPEUTICS, INC. (Delaware (US)) … WebAbout Tempest Therapeutics Developing therapeutics designed to effectively treat cancer. Tempest Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. WebIn 2013, the company formed a partnership with AstraZeneca to develop treatments for cardiovascular, metabolic, and renal diseases, as well as cancer, in 2015, the company formed a partnership with Merck & Co. to develop treatments for cancer, and in 2016 the company formed a partnership with Vertex Pharmaceuticals to develop treatments for … building cpd uk